CURRICULUM VITAE

CURRICULUM VITAE
1. PERSONAL DATA
Surname:
Rollason
Name:
Victoria Michèle
Professional address:
Division of Clinical Pharmacology and Toxicology
Department of Anaesthesiology, Pharmacology and Intensive care
University Hospitals of Geneva
Rue Gabrielle-Perret-Gentil 4
1211 Geneva 14
Tel: +41 (0)22.382.99.34 / +41 (0)79.553.22.18
E-mail: [email protected]
Languages
English: mother tongue
French: mother tongue
German: good knowledge
Italian: good knowledge
2. PRESENT POSITION
Since 2004
Adjunct Pharmacist, Division of Clinical Pharmacology and Toxicology, Department of
Anaesthesiology, Pharmacology and Intensive care (Prof Jules Desmeules).
Since 2013
Adjunct Pharmacist, Clinical Trial Unit, Medical Directorate (Prof. Arnaud Perrier/Prof Jules
Desmeules).
1
3. DIPLOMAS
2015
Certificate in Pharmacoepidemiology and Pharmacovigilance, London School of Hygiene and
Tropical Medicine, London, UK.
2004
Clinical Pharmacologist SGKPT/SSPTC, Swiss Society of Clinical Pharmacology and Toxicology.
2003 Doctor of Pharmaceutical Sciences, Thesis No 3473, "Pain in the elderly - An updated review of
current research and therapeutic practice, Future perspectives suggested by novel experiments
with tramadol”, University of Geneva, Geneva, Switzerland.
1992
Degree in pharmacy (diploma), Department of Sciences, University of Geneva, Geneva,
Switzerland.
1987
Swiss Maturité type B, Latin section, Collège de Sismondi, Geneva, Switzerland.
4. OTHER TRAINING AND EDUCATION
2014
Les fondamentaux de la stratégie des gains mutuels, centre de formation HUG, Geneva,
Switzerland.
2014
Secutrial, Geneva, Switzerland.
2014
Coding with MedDRA, Bern, Switzerland.
2014
Latest update on Human Research Act (HRA) - Impact on regulation of clinical trials in
Switzerland, Workshop, Bern, Switzerland.
2013
Dealing with Difficult Pain Syndromes - Persistent Pain after Surgery, EFIC Refresher course, 8th
Congress of the European Federation of IASP Chapters (EFIC), Florence, Italy.
2013
Clinical therapeutics mechanism-based pharmacological pain treatment. EFIC Refresher course, 8th
Congress of the European Federation of IASP Chapters (EFIC), Florence, Italy.
2013
Adverse drug reactions: clinical approach and differential diagnosis as the basis of case quality,
ISoP, Pisa, Italy.
2013
3rd Annual Pharmacovigilance SMi meeting, SMi, London, UK.
2013
Good governance in (clinical) research with human data and tissue, 4th Symposium of the Swiss
Clinical Trial Organisation, Geneva, Switzerland.
2013
Thèmes de pharmacologie et de toxicologie cliniques, Master of Advanced Studies (MAS) in
Hospital Pharmacy, Geneva-Lausanne School of Pharmacy, Geneva, Switzerland.
2013
System and site inspections - practical examples, Swissmedic Workshop on GCP Inspections, Bern,
Switzerland.
2013
Assuring best practice in signal detection and management for GVP, SMi, London, UK.
2013
Clinical Pharmacology Curriculum Review Course, Clinical track. American Society of Clinical
Pharmacology and Therapeutics (ASCPT), Indianapolis, USA.
2
2012
Benefit-risk assessment for the new PSUR, SMi, London, UK.
2009
International Society of Drug Bulletins: pharmacovigilance workshop and committee meeting,
Bielefeld.
2005
Pharmacovigilance - Principles and practice, European Association of Clinical Pharmacology and
Therapeutics (EACPT) / EMEA / ISOP, Stockholm, Sweden.
2002
Séminaire pratique de pharmacocinétique les doigts sur le clavier, Séminaire Vaud-Genève de
formation post-graduée et continue en pharmacologie clinique, Begnins, Switzerland.
2001
Le développement du médicament, Séminaire de formation post-grade et continu, University
Hospitals of Geneva, Geneva, Switzerland
2001
Le protocole de recherche clinique, Séminaire de formation post-grade et continu, University
Hospitals of Geneva, Geneva, Switzerland.
2001
Analyse statistique des données, niveau 2, Centre de formation HUG, Geneva, Switzerland.
2001
One-week Workshop in Basic Pharmacokinetics, University of Manchester, Prof Rowland, Arosa,
Switzerland.
2001
Analyse statistique des données, niveau 1, Centre de formation HUG, Geneva, Switzerland.
2000
Basic Training in Pharmacovigilance, European Society of Pharmacovigilance (ESOP), Verona, Italy.
1999
Writing and publishing in the Sciences, Centre for the Study and Teaching of Writing, McGill
University, Geneva, Switzerland.
1999
Writing systematic reviews in pain, IASP, Special Interest Group for Systematic Reviews, Oxford,
UK.
5. PROFESSIONNAL ACTIVITIES
Since 2013 -
Clinical Pharmacologist / Adjunct pharmacist, Division of Clinical Pharmacology and
Toxicology, University Hospitals of Geneva, Geneva.
In charge of safety management in clinical trials, creation and management of DSMBs
and management of medication of clinical studies.
Since 2004 -
Clinical Pharmacologist / Adjunct pharmacist, Division of Clinical Pharmacology and
Toxicology, University Hospitals of Geneva, Geneva.
In charge of the regional pharmacovigilance centre of Geneva.
Jan 2003 - Oct 2004
Clinical Pharmacologist, Division of Clinical Pharmacology and Toxicology, University
Hospitals of Geneva, Geneva.
3
Oct 2000 - Dec 2002
Research assistant, Division of Clinical Pharmacology and Toxicology, University
Hospitals of Geneva, Geneva.
Mar 1999 - Oct 2000
Research assistant, Gerontopharmacology unit, Department of Geriatrics, University
Hospitals of Geneva, Geneva.
Jan 1993 - Feb 1999
Pharmacist, Pharmacie Principale, Balexert branch, Geneva.
6. TEACHING (HOURS PER AN)
Pregraduate
Geneva-Lausanne School of Pharmacy (EPGL)
rd
Since 2014 Courses of Clinical Pharmacology for students in 3 grade (last year of Bachelor), GenevaLausanne School of Pharmacy, Faculty of Sciences, University of Geneva, "Module
Pharmacologie et toxicologie cliniques", 23H001.

"Pharmacologie sociale 2: Le pharmacien et les sources d'information", 2 hours.

"Pharmacologie et sécurité du médicament: Médicaments et grossesse", 2 hours.

"Pharmacologie et sécurité du médicament: Médicaments et allaitement", 2 hours.
th
st
Since 2009 Courses of Clinical Pharmacology for students in 4 grade (1 year of Master), GenevaLausanne School of Pharmacy, Faculty of Sciences, University of Geneva, "Module
Medicaments et Maladie", 14H003.

"La bronchopneumopathie chronique obstructive (BPCO)", 2 hours.

"Les syndromes médicamenteux", 1 hour.
Faculty of medicine / Section of dental medicine
th
Since 2014 Courses of Clinical Pharmacology to the students in 5 grade (last year of Master), Section of
Dental medicine, Faculty of Medicine, University of Geneva

"Ostéonecroses de la mâchoire sous bisphosphonates", 1 hour.

"Pharmacologie générale", 2 hours.
Post-graduate and continuing education
Since 2015 Scientific seminar of the Division of Clinical Pharmacology and Toxicology, "Vigilyze: de la
théorie à la pratique", University Hospitals of Geneva, Geneva, 1 hour.
4
Since 2014 Scientific seminar of the Division of Clinical Pharmacology and Toxicology, "Le signal en
pharmacovigilance: qu'est-ce que c'est exactement?", University Hospitals of Geneva,
Geneva, 1 hour.
Since 2013
Programme de formation de base obligatoire des médecins nouvellement engagés aux
Hôpitaux
Universitaires
de
Genève,
"Risque
nosocomial
médicamenteux
-
Pharmacovigilance", University Hospitals of Geneva, Geneva, 2 hours.
2013
th
EFIC Refresher course "Pharmacogenetics of analgesics for the non-expert". 8 Congress of
the European Federation of IASP Chapters (EFIC), Florence, Italy, 2 hours.
2013
Master of advanced studies (MAS) in hospital pharmacy. Seminar "Thèmes de pharmacologie
et de toxicologie cliniques", "Actualité de pharmacovigilance: les nouveaux anticoagulants
oraux (NACO)", Geneva-Lausanne School of Pharmacy, University of Geneva, Geneva, 1 hour.
Since 2012 Diploma of Advanced Studies (DAS) - Management of Clinical Trials, Module 3, "Safety
Management and Drug Development", University of Geneva – University Hospitals of Geneva,
Geneva, 5 hours.
2012
Integration seminar for quality officers, "Les vigilances: pharmacovigilance", University
Hospitals of Geneva, Bossey, 1 hour.
2012
Certificate of Advanced Studies (CAS) - Management of Clinical Trials, Module 5, "Safety
Management", University de Geneva - University Hospitals of Geneva, Geneva, 3 hours.
Since 2011 Master of Advanced Studies in Toxicology (MAS), "Pharmacovigilance in clinical studies"",
University of Geneva - University Hospitals of Geneva, Geneva, 4 hours.
Since 2011 Seminar "Bonnes pratiques des études cliniques",
"Session
interactive:
possibilités
d’événements indésirables: comment les reconnaître et les déclarer ?", University Hospitals of
Geneva - Faculty of Medicine, Geneva, 2 hours.
Since 2011 Formation des cadres aux compétences en management "Gérer les incidents en
milieu
hospitalier ", "Pharmacovigilance", University Hospitals of Geneva, Geneva, 1 hour.
2010
Annual Congress of the Swiss Society of Intensive Care Medicine, Workshop: "Updates in
pharmacovigilance", Lausanne, 4 hours.
2010
Master in Advanced Sciences (MAS) in hospital pharmacy. Seminar "Thèmes de
pharmacologie et de toxicologie cliniques", "Pharmacovigilance et OTC. L'exemple des
inhibiteurs de la pompe à protons (IPP) et de l'orlistat". Geneva-Lausanne School of
Pharmacy, University of Geneva, Geneva, 1 hour.
2009
Scientific seminar of the Division of Clinical Pharmacology and Toxicoloy, University Hospitals
of Geneva, "Impact de la dioxine sur la santé humaine", Geneva, 1 hour.
5
2007
nd
Eudipharm seminar on Evaluation and use of medicinal products during pregnancy - 2
Edition, "Pregnancy surveillance in Geneva: from 1994 to today", Eudipharm, University
Hospitals of Geneva, Geneva, 2 hours.
2007
Scientific seminar of the Division of Clinical Pharmacology and Toxicology, University Hospitals
of Geneva, "Suivi de grossesse: de 1994 à aujourd'hui", Geneva, 1 hour.
2007
Formation des groupes de recueil et d’analyse des incidents, "Pharmacovigilance", University
Hospitals of Geneva, Geneva, 1 hour.
2007
Physicians of the Hôpital de la Tour, "Le placebo et l’effet placebo", Hôpital de la Tour,
Geneva, 1 hour.
Since 2006
Scientific seminar of the Division of Clinical Pharmacology and Toxicology, University Hospitals
of Geneva, "La pharmacovigilance", Geneva, 2 hours.
Since 2006
Scientific seminar of the Division of Clinical Pharmacology and Toxicology, University Hospitals
of Geneva, "Pharmacovigilance: utilisation de Vigiflow", Geneva, 2 hours.
2006
Diplôme d’Etudes Supérieures Spécialisées (DESS) in hospital pharmacy. Seminar "Thèmes de
pharmacologie et de toxicologie cliniques", "Médicaments, grossesse et allaitement", GenevaLausanne School of Pharmacy, University of Geneva, Geneva, 1 hour.
Para-medical
2015
Course to diplomed nutritionists and dieteticien. "Nutrition et polyarthrites rhumatoïdes.
Médication et effets secondaires", HEIG-VD, Yverdon, 1 hour.
Since 2012 Courses to the students in midwifery, Bachelor 3
rd
year, "Prescription et utilisation de
medicaments par la sage-femme", HEDS, Geneva, 3 hours.
st
Since 2012 Courses to the students in midwifery, Bachelor 1 year, "Médicaments et allaitement", HEDS,
Geneva, 2 hours.
2010-2011 Courses to the nurse students, preparatory year, "Pharmacologie: antalgie et sédation",
HEDS, Geneva, 3 hours.
2007
Course to the "garçons de pharmacie", "Le placebo et l’effet placebo", Pharmacy of the
Univeristy Hospitals of Geneva, Geneva, 1 hour.
rd
Since 2006 Courses to the students in nutrition and dietetics. Bachelor 3 year. "Module: se nourrir et se
soigner autrement", "Le placebo et l’effet placebo", HEDS, Geneva, 2 hours.
2004
Course to the assistants in pharmacy of the University Hospitals of Geneva. "Particularités de
la prescription gériatrique", Pharmacy of the University Hospitals of Geneva, Geneva, 1 hour.
6
2001
Course to the students training as medical assistants. "Recherche et Qualité de l'Information
scientifique". Centre d’enseignement de Professions de la Santé et de la Petite Enfance,
Geneva, 6 hours.
2000-2001 Course to the students training as medical secretaries, "Pharmacologie générale", Ecole BER,
Geneva, 4 hours.
1999-2001 Courses to the
students
in
physiotherapy.
"Recherche
et
Qualité
de
l'Information
scientifique", HEDS, Geneva, 6 hours.
7.
ADMINISTRATION / FONCTIONS OFFICIELLES
Since 2016
Treasurer of the Swiss Society of Clinical Pharmacology and Toxicology (SSPTC).
Since 2015
Member of the board of the Swiss Society of Clinical Pharmacology and Toxicology (SSPTC).
Since 2015
Vice-president of the Swiss-Austria Chapter of the International Society of Pharmacovigilance
(ISOP)
Since 2008
Member of the multidisciplinary working group "Extravasation".
Since 2006 Representative of the Division of Clinical Pharmacology and Toxicology at multi-year
pharmacovigilance meetings and other ad hoc meetings on pharmacovigilance, Swissmedic,
Bern.
2009
Member of the multidisciplinary working group "Acenocoumarol in geriatrics".
2009
Member of the multidisciplinary working group "Principes pour la préparation et
l’administration de médicaments".
Since 2005
8.
Member of the multidisciplinary working group "Extravasation of cytostatiques".
DISTINCTIONS
Sytematic Review Prize 2007, IADR Evidence Based Dentistry Network, for the systematic review protocol:
"Interventions for treating osteonecrosis of the jaw bones associated with bisphosphonates".
7
9.
SOCIETES
Société Suisse de Pharmacologie et de Toxicologie Clinique (SSPTC), 2004 - .
International Society of Pharmacovigilance (ISOP), 2013 –
Swiss Association of Pharmaceutical Professionals (SwAPP), 2014 Société Suisse des pharmaciens Pharmasuisse, 2014 –
Association suisse des pharmaciens de l'administration et des hôpitaux (GSASA), 2014 –
European Society of Clinical Pharmacy (ESCP), 2014-
10. SCIENTIFIC ROLES
Reviewer
Drugs Aging
Pharmacogenomics
Personalized Medicine
Journal of Drug Delivery
11. GRANTS
Projet recherché et développement n° 19-2014-II (50'000 CHF), University Hospitals of Geneva, Geneva,
Switzerland. Observational Study to Evaluate the Impact of the CYP3A4/5 and P-gp Pharmacogenetics and
Phenotypic Activity on the Safety of Rivaroxaban in Routine Clinical Practice. Bavamian S, Rollason V, Daali Y,
Fontana P, de Moerloose P, Boehlen F, Reny JL, Rebsamen M, Combescure C, Desmeules J.
12. PATENTS
"Combined use of oral anticoagulants and related methods". P1577EP00
8
13. THESIS DIRECTOR
PhD in science (section pharmacy)
2012
Mrs Liliane Gschwind, "Anticoagulation par antivitamines K: analyse des interactions médicamenteuses et des
polymorphismes génétiques à l’origine de la variabilité de la réponse et des risques liés à l’acénocoumarol".
Thèse No 28993. University of Geneva.
Diploma of Master of Advanced Studies (MAS) in hospital pharmacy
2010
Mrs Claudia Zaugg, "Evaluation et optimisation du Therapeutic Drug Monitoring en néonatologie", GenevaLausanne School of Pharmacy, University of Geneva and Lausanne.
2009
Mrs Liliane Gschwind, "Etat des lieux et amélioration de la prescription de l’acénocoumarol" Geneva-Lausanne
School of Pharmacy, University of Geneva and Lausanne.
Master thesis in Pharmacy
2016
Mrs Sabrina Boumaiza, "Analyse rétrospective de l’issue d’expositions à des médicaments lors de la grossesse
signalées au service de pharmacologie et toxicologie cliniques des hôpitaux universitaires de Genève de 2004 à
2015".
Mrs Camille Lenoir, " Les inhibiteurs de la pompe à protons : sur-utilisation, effets indésirables et interactions
au travers de trois études cliniques".
Mrs Nour Khatteche, "Contribution à l’étude critique des rapports de cas publiés de nécrose de la
mâchoire induite par les bisphosphonates"
2015
Mr Malek Ben Mansour, "Chronopharmacology and risk of interaction between clopidogrel and omeprazole in
hospitalised patients", Geneva-Lausanne School of Pharmacy, University of Geneva and Lausanne.
2014
Mrs Rita Benkirane. "Etude de corrélation des phénotypes et génotypes dans une cohorte de patients
anticoagulés par antivitamine K : Evaluation du rôle des interactions médicamenteuses de l’impact des
inhibiteurs de la pompe à protons sur l’anticoagulation et le risque de saignement", Geneva-Lausanne School of
Pharmacy, University of Geneva and Lausanne.
Mrs Liene Adlere. "Snapshot of prescribing practice for clopidogrel and esomeprazole co-prescription and a
cost evaluation of guidelines application". Geneva-Lausanne School of Pharmacy, University of Geneva and
Lausanne.
9
2013
Mrs Sara Oualidi. "Importance du suivi dans l’évaluation du risque des grossesses exposées aux médicaments".
Geneva-Lausanne School of Pharmacy, University of Geneva and Lausanne.
Thesis work for the Diploma of Advanced Studies (DAS) in Clinical Trials Management
2016
Mrs Giovanna Zacchetti, "Protocol Analysis and Elaboration of Documentation of Two Observational Studies on
Antithrombotic Drugs for Submission to the Ethic Committee".
Mrs Virginie Licker, "New ICH E2B (R3) message for electronic transmission of ICSR: major challenges of
implementation in Europe".
2015
Mrs Sabine Bavamian, "Active surveillance of the adverse effects new oral anticoagulants in a hospital setting: a
protocol". University of Geneva.
Mrs Alexandra Laverrière, "Bonnes pratiques de pharmacovigilance: politique des éditeurs dans le cadre de la
publication de case reports". University of Geneva.
Mrs Ursula Loizides, "Trial Master File structure and organisation for the Phase 3 and 2 studies of moxidectin in
Africa sponsored by WHO". University of Geneva.
2014
Mrs Shirin Pour Nourmohammadi, February 2014, "Clinical trials and data safety monitoring boards (DSMB),
review of a year of protocols submitted to the HUG central ethics committee", University de Geneva.
Mrs Shalini Jayasekar, "The new pharmacovigilance legislation. Consequences for the Industry, the Clinical
Trials Centers and the Ethics Committees", University de Geneva.
Mr Alain Matthey, " Submission to the Swiss regulatory authorities (Swissmedic) of a category C publicly funded
clinical trial entitled: Exploring the role of the GABAergic modulation in pain transmission in human: Effect of
the GABAA agonist clobazam and N-desmethylclobazam on central sensitization: a pharmacodynamic and
pharmacokinetic study in healthy volunteers". University de Geneva.
Mr Laurent Barnes, "Effets atrophiques sur la peau des corticostéroïdes topiques", University de Geneva.
Mrs Carolina Sargenti. " Analysis of American Trypanosomiasis world status, outline of evidences and gap
definition: A possible way to harmonization for a better disease management". University de Geneva.
2013
Mrs Fabiana Tirone, "Pharmacovigilance: experience through two phase IV clinical trials" University de Geneva.
Mrs Helena Pontes, "Safety Signal Detection: The relevance of literature review", University de Geneva.
10
14. PUBLICATIONS
1.
ORIGINAL ARTICLES PUBLISHED IN PEER REVIEWED JOURNALS
2016
1.
Rollason V, Laverrière A, MacDonald LC, Walsh T, Tramèr MR, Vogt-Ferrier NB. Interventions for
treating bisphosphonate-related osteonecrosis of the jaw (BRONJ).Cochrane Database Syst Rev. 2016
Feb 26;2:CD008455. doi: 10.1002/14651858.CD008455.pub2
2.
Vernaz N, Rollason V, Adlere L, Combescure, Poncet A, Bonnabry P, Desmeules J. Snapshot of the
prescribing practice for the clopidogrel and esomeprazole coprescription and cost evaluation of the
application guidelines. Pharma Res Per 2016;4(3), e00234.
2015
3.
V. Rollason, L. Gschwind, F. Boehlen, M. Rebsamen, C. Combescure, A. Matthey, P. Bonnabry, P.
Dayer, J. A. Desmeules.
P-glycoprotein: a clue to vitamin K antagonist stabilization.
Pharmacogenomics 2015;16(2):
2014
4.
Girardin F, Poncet A, Blondon M, Vernaz N, Rollason V, Chalandon Y, Dayer P, Combescure C.
Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a
cost-effectiveness analysis. Lancet Psychiatry 2014;1(1):55-62.
5.
Marking U, den Boer M, Kumar Das A, Mohammed Ahmed E, Rollason V, Davidson R, Ritmeijer K.
Hypokalaemia induced rhabdomyolysis after treatment of post-kala-azar dermal leishmaniasis (PKDL)
with high dose AmBisome® in Bangladesh – A case report. PLoS Negl Trop Dis. 2014;8(6):e2864.
6.
Fonzo-Christe C, Guignard B, Zaugg C, Pfister R, Desmeules J, Rollason V, Posfay Barbe C, Corbelli R,
Gervaix A, Rimensberger P, Bonnabry P. "Impact of clinical decision support guidelines on gentamicin
therapeutic drug monitoring in newborns". Ther Drug Monitor. 2014;15(3):326-43.
2013
7.
Gschwind L, Rollason V, Daali Y, Bonnabry P, Dayer P, Desmeules JA. Role of P-glycoprotein in the
uptake/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model.
Basic Clin Pharmacol Toxicol 2013;113(4): 259-65.
8.
Gschwind L, Rollason V, Boehlen F, Rebsamen M, Combescure C, Grünenwald M, Matthey A,
Bonnabry P, Dayer P, Desmeules JA. Impact of CYP2C9 polymorphisms on the vulnerability of drugdrug interactions during acenocoumarol treatment. Pharmacogenomics 2013;14(7):745-53.
9.
Gschwind L, Rollason V , Lovis C, Boehlen F, Bonnabry P, Dayer P, Desmeules JA. Identification and
weighting of the most critical "real-life" drug-drug interactions with acenocoumarol in a tertiary care
hospital. Eur J Clin Pharmacol 2013;69(3):617-27.
11
2.
REVIEW ARTICLES PUBLISHED IN PEER REVIEWED JOURNALS
2015
1.
Besson M, Samer C, Rollason V, Dayer P, Desmeules J. Providing Quality Therapeutics in Switzerland:
Role of the Stakeholders and Recent Incentives for Further Improvements. Clin Ther. 2015 Jul
1;37(7):1588-92.
2.
L. Barnes, G. Kaya, V. Rollason. A systematic review of the skin atrophy induced by topical
corticosteroids: an adverse event that still needs to be clinically assessed. Submitted to Drug Saf (Dec
2014).
2014
3.
H. Pontes, M. Clement, V. Rollason. Safety signal detection: the relevance of literature review. Drug
Saf. 2014;37(7):471-9.
4.
Rollason V, Samer C, Daali Y, Desmeules J. Prediction by pharmacogenetics of safety and efficacy of
non-steroidal anti-inflammatory drugs: a review. Curr Drug Metab, 2014;15(3):326-43.
2013
5.
Samer CF, Rollason V, Ing Lorenzini K, Daali Y, Desmeules JA. Intérêt des outils d’investigation des
enzymes métaboliques en pratique clinique. Douleur Analg, 2013;26:241-7.
6.
Rollason V, Samer C, Desmeules J. Pharmacogénétique des anti-inflammatoires non-stéroïdiens.
Douleur Analg 2013;26:195-202.
7.
Samer CF, Ing Lorenzini K, Rollason V, Daali Y, Desmeules J. Application of CYP450 testing in the clinical
setting, Mol Diagn Ther 2013;17(3):165-84.
2012
8.
Pereira MA, Senhaji S, Rollason V, Jungo NC, Luthy C, Piguet V. Antalgie medicamenteuse et grossesse.
Rev Med Suisse 2012;8(347):1389-92, 1394.
2010
9.
Vogt-Ferrier NB, Hugentobler M, Uebelhart B, Tramèr M, Rollason V. Interventions for treating
osteonecrosis of the jaw bones associated with bisphosphonates (Protocol). The Cochrane Library
2010, Issue 4, Chichester: Wiley.
2008
10. Rollason V, Samer C, Piguet V, Dayer P, Desmeules J. Pharmacogenetics of analgesics: toward the
individualization of prescription. Pharmacogenomics. 2008;9:905-33.
12
2003
11. Desmeules J, Rollason V, Piguet V, Dayer P: Clinical pharmacology and rationale of analgesic
combinations. Eur J Anaesthesiol 2003;20 (28 Suppl): 7-12.
12. Rollason V, Vogt N. Reduction of polypharmacy in the elderly. A systematic review of the role of the
pharmacist. Drugs Aging 2003; 20:817-32.
2001
13. Rollason V, Desmeules J, Vogt N. Effet analgésique des opiacées en usage cutané: quelle est leur
efficacité. Thérapie 2001;56(1):23-27.
3.
LETTERS TO THE EDITOR PUBLISHED IN PEER REVIEWED JOURNALS
2016
1.
V. Rollason, L. Spahr, M. Escher. Acute severe liver injury due to an artisanal flower pollen preparation
in a patient with high CYP3A4 enzyme activity: a case-report. Eur J Clin Pharmacol. 2016
Apr;72(4):507-8).
2015
2.
Rollason V, Desmeules JA. Use of metamizole in children and the risk of agranulocytosis: Is the benefit
worth the risk? Eur J Anaesthesiol. 2015 Dec;32(12):837-8
2012
3.
Iancu Ferfoglia R, Rollason Gumprecht V, Villaneau D, Vogt-Ferrier N. A case of pancytopenia with
signs of pulmonary fibrosis and liver cirrhosis secondary to low-dose methotrexate therapy in a patient
with rheumatoid arthritis. European Geriatric Medecine 2012;3:53-6.
2011
4.
Rollason Gumprecht V, Schnetzler B, Sunthorn H, Rebsamen M, Desmeules J. Death following "pill-inthe-pocket" treatment with propafenone and verapamil in a CYP2D6 poor metaboliser. Heart
published online November 4, 2011. Available at: http://heart.bmj.com/content/97/19/1626.1/reply.
4.
REVIEW ARTICLES PUBLISHED IN NON PEER REVIEWED JOURNALS
2013
1.
Rollason V, Desmeules J. Pharmacogenetics of analgesics for the non-expert. EFIC Refresher
course.8th Congress of the European federation of IASP Chapters (EFIC), Florence, Italy, 2013.
2.
Rollason V, Roulet L, Samer C, daali Y, besson M, piguet V, escher M, Dayer P, Desmeules JA. Rotation
of opioids: from theory to practice. SIMPAR 2013, Study in Multidisciplinary Pain Research, 5th
Meeting, Pavia, Italy, In: Minerva Anesthesiologica 2013;79 (Suppl 1 to No 3):10-1.
13
2004
3.
Vogt-Ferrier N, Cabotte E, Moret V, Diet M-C, Déramé L, Jan-Iwaniec F, Schaerer G, Beytrison I,
Ducloux D, Guisado H, Balahoczky M, Rollason V, Pautex S. Constipation: un syndrome gériatrique
mal-aimé. Med Hyg 2004;62:2309-19.
2001
4.
Rollason V, Christe C, Vogt N. Problèmes pratiques et éthiques des essais cliniques en gériatrie. Med
Hyg 2001;59:838-42.
5.
Prescription médicale d'hydromorphone pour le traitement de la douleur en gériatrie. CAPP-Info,
Bulletin d'information du CAPP (Contact Avis Pharmacologique et Pharmaceutique), No 16, March
2001.
2000
6.
Phytothérapie. Pharmaflash, Vol 27, No 3, 2000.
7.
Homéopathie. CAPP-Info, Bulletin d'information du CAPP (Contact Avis Pharmacologique et
Pharmaceutique), No 13, July 2000.
8.
Liberek C, Desmeules J, Vogt N, Rollason V, Dayer P. Le syndrome sérotoninergique médicamenteux:
un risque à ne pas négliger. Med Hyg 2000;56:834-42.
9.
Rollason V, Bonnabry P, Vogt N. Réduire la plurimédication chez la personne âgée: du vœu pieux à des
solutions applicables. Med Hyg 2000;58:818-25.
1999
10. Place des anti-inflammatoires non stéroïdiens topiques en gériatrie. CAPP-Info, Bulletin d'information
du CAPP (Contact Avis Pharmacologique et Pharmaceutique), No 6, October 1999.
5.
CHAPTERS IN BOOKS
2010
1.
Rollason V, Samer C, Besson M, Piguet V, Daali Y, Dayer P, Desmeules JA. Pharmacogénétique des
analgésiques. In : L’analgésie périopératoire : nouvelles stratégies et perspectives. JEPU 2010.
2009
2.
Rollason V, Samer C, Daali Y, Piguet V, Dayer P, Desmeules JA. Chapitre 19 Pharmacogénétique des
analgésiques. In : Douleurs : physiologie, physiopathologie et pharmacologie. Bouhassira D, Calvino B,
editors. Reuil-Malmaison: Arnette Wolters Kluwer France; 2009:291-315.
14
2007
3.
Desmeules J, Rollason V, Cedraschi C, Piguet V, Allaz A_F, Dayer P. Chapter 10 Advances in analgesics
and NSAIDs for the treatment of spinal disorders. In: Pain Best Practice and Research Compendium.
Breivik H, Shipley M, editors. Edinburgh: Elsevier, 2007:93-103.
6.
ORAL COMMUNICATIONS PRESENTED AT INTERNATIONAL MEETINGS
2014
1.
Welle I, Rollason V, Desmeules J, Chopard P. Oral Anticogagulation Quality Control Among Inpatients:
st
Digging into the Data. ISQUA's 31 International Conference. Rio de Janeiro, Brésil. October 2014.
2.
F. Girardin, A. Poncet, M. Blondon, V. Rollason, N. Vernaz, Y. Chalandon, P. Dayer, C. Combescure.
Cost-effectiveness of monitoring white blood cell count to prevent agranulocytosis in psychotic adults
on clozapine. European and Swiss Congress of Internal Medicine. Geneva, Switzerland. 14-16 May
2014.
2013
3.
Rollason V, Gschwind L, Boehlen F, Rebsamen M, Combescure C, Grünenwald M, Matthey A,
Bonnabry P, Dayer P, Desmeules JA. Impact of CYP2C9 polymorphisms on the vulnerability to
th
pharmacokinetic drug-drug interactions during acenocoumarol treatment. 11 EACPT Congress 2013,
Geneva, Switzerland. 28-31 August 2013.
2009
4.
Zaugg C, Guignard B, Pfister R, Rimensberger P, Rollason V, Desmeules J, Fonzo-Christe C, Bonnabry P.
Gentamicin and vancomycin therapeutic drug monitoring in newborns: evaluation of practices. 38th
European Symposium on Clinical Pharmacy, ESCP - GSASA Symposium, Geneva, Switzerland, 3-6
November 2009.
5.
Gschwind L, Rollason Gumprecht V, Boehlen F, Dayer P, Bonnabry P, Desmeules J. Identification and
ponderation of the most critical drug-drug interactions with acenocoumarol, PT-01. 38th European
Symposium on Clinical Pharmacy, ESCP - GSASA Symposium, Geneva, Switzerland, 3-6 November
2009.
15